Motilal Oswal Mutual Fund

Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth

Equity: Sectoral-Pharma - Growth (Open ended)
Risk levelCategoryBenchmark
Copyright © 2026 sharpely. All rights reserved.
Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: Nifty MidSmall Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹12.63+0.65%
07 Sept 2026

Holdings Analysis

Equity, debt and cash allocation snapshot with market cap distribution for Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth.

Asset Allocation

As on 31 Jul 2026
Equity
99.76%
Others
0.24%

Market Cap Distribution

Mid Cap (68.3%)
Small Cap (31.7%)

Historical Asset Allocation

Asset31 Jul 202630 Jun 202631 May 202630 Apr 202631 Mar 202628 Feb 2026
Equity99.76%100.29%99.92%100.04%99.81%99.84%
Debt0.00%0.00%0.00%0.00%0.00%0.00%
Others (incl. cash)0.24%-0.30%0.08%-0.04%0.19%0.16%
Commodities0.00%0.00%0.00%0.00%0.00%0.00%
Real Estate0.00%0.00%0.00%0.00%0.00%0.00%

Portfolio Snapshot

No. of Securities
31
P/E Ratio
39.07
P/B Ratio
4.80
Top Holding %
10.77%
Top 5 Holdings %
39.00%
Top 10 Holdings %
59.90%
AUM
₹47 Cr
Expense Ratio
0.79%
Since Inception
13.84%
Max Drawdown
-0.17%

Top Portfolio Holdings by Weight

Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
InstrumentSectorNo. of SharesValue (Rs. Cr)WeightChange
Laurus Labs Ltd.Healthcare27,7595.0410.77%1.46%
Lupin Ltd.Healthcare17,3264.188.94%-0.32%
Fortis Healthcare Ltd.Healthcare37,1793.517.50%-0.36%
Aurobindo Pharma Ltd.Healthcare19,7483.126.66%-0.23%
Glenmark Pharmaceuticals Ltd.Healthcare10,7422.45.13%-0.10%
Alkem Laboratories Ltd.Healthcare4,1752.45.13%-0.01%
Biocon Ltd.Healthcare50,9022.174.63%-0.07%
Mankind Pharma Ltd.Healthcare8,0771.994.26%-0.28%
Ipca Laboratories Ltd.Healthcare9,9101.733.70%-0.02%
Krishna Institute of Medical Sciences LtdHealthcare18,4961.493.18%-0.15%
Aster DM Quality Care Ltd.Healthcare18,0641.493.17%0.04%
Gland Pharma Ltd.Healthcare5,6851.423.04%-0.09%
Sai Life Sciences Ltd.Healthcare9,8441.292.76%0.08%
Neuland Laboratories Ltd.Healthcare6151.172.50%-0.03%
Wockhardt Ltd.Healthcare5,8921.152.47%-0.06%
Acutaas Chemicals Ltd.Healthcare3,7001.152.45%-
Dr. Lal Pathlabs Ltd.Healthcare5,5601.062.26%0.24%
Ajanta Pharma Ltd.Healthcare3,0051.042.22%-0.05%
Abbott India Ltd.Healthcare3721.032.21%0.12%
Narayana Hrudayalaya Ltd.Healthcare4,93012.14%-0.01%
1 / 2

Sector-wise Portfolio Allocation

Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
Sector31 Jul 202630 Jun 202631 May 202630 Apr 202631 Mar 202628 Feb 2026
Healthcare
99.76%
100.29%
99.92%
100.04%
99.81%
99.84%

Equity Insights

A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.

Style Analysis

Value score

28.3 / 100

Weighted average Value score is 28.3. This indicates that portfolio is relatively reasonably valued using composite of value measures.

Price Momentum score

69.1 / 100

Weighted average Price Momentum score is 69.1. This indicates that portfolio has average momentum using composite of momentum measures.

Quality score

79.2 / 100

Weighted average Quality score is 79.2. This indicates that portfolio has high quality using composite of quality measures.

QVM score

66.2 / 100

Weighted average QVM score is 66.2. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.

Red Flags

Earnings manipulation risk (Beneish M-score)
Following stocks have high risk of potential earnings manipulation (Beneish M-score > -1.78):
NameValue
Abbott India Ltd.-1.38
Neuland Laboratories Ltd.-1.62
Ajanta Pharma Ltd.-1.58
Narayana Hrudayalaya Ltd.-0.14
Declining revenues
Following companies have seen their sales decline for 2 consecutive quarters (measured on yoy basis): Natco Pharma Ltd.
Negative cash flow from operations
Following companies have not generated positive operating cash flow for 2 consecutive financial years: Onesource Specialty Pharma Ltd.

Frequently Asked Questions

What are the top holdings of Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth?
The top holdings of Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth as of 31 Jul 2026 are Laurus Labs Ltd. (10.77%), Lupin Ltd. (8.94%), Fortis Healthcare Ltd. (7.50%), Aurobindo Pharma Ltd. (6.66%), Glenmark Pharmaceuticals Ltd. (5.13%). These top 5 stocks together account for 39.00% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth hold in its portfolio?
Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth holds 31 stocks in its portfolio as of 31 Jul 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth?
As of 31 Jul 2026, Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth's top sector allocations are Healthcare (99.76%). You can find detailed sector allocation above.
What is the equity and debt allocation of Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth?
As of 31 Jul 2026, Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth has 99.76% allocated to equity, and 0.00% to debt. You can also check the historical trends above.
What is the market cap allocation of Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth?
As of 31 Jul 2026, Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth's market cap allocation is - in large caps, 68.29% in mid caps, and 31.71% in small caps.
What is the PE ratio of Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth's portfolio?
The portfolio PE ratio of Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth is 39.07 as of 31 Jul 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth?
A credit rating breakdown is not available for Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth — its non-equity allocation was 0.00% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth?
The latest portfolio disclosure for Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth is as of 31 Jul 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.